Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations

by Chen, Z.-H, Deng, J.-Y, Wei, X.-W, Wu, Q., Wu, Y.-L, Xu, C.-R, Zhang, X.-C, Zhou, Q., Zhu, D.-Q
Published 2022

Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer

by Bai, H., Chen, H., Cseh, A., Duan, J., Huang, D.C.-L, Tian, Y., Wang, J., Wang, X., Wang, Y., Wu, Y.-L, Xue, Z., Zhao, J.
Published 2022